Psoriasis, COVID-19 and shielding by Becher, G. & Burden, A.D.
COMMENTARY
BJD
British Journal of Dermatology
Psoriasis, COVID-19 and shielding
DOI: 10.1111/bjd.20055
Linked Article: Mahil et al. Br J Dermatol 2021; https://doi.
org/10.1111/bjd.19755.
The COVID-19 pandemic has presented clinicians managing
immune-mediated inflammatory diseases (IMIDs) such as pso-
riasis, with many challenges. Patients with severe psoriasis
have an increased prevalence of risk factors for severe COVID-
19 including obesity, hypertension, diabetes and male sex.1
Moreover, many systemic treatments for psoriasis are known
to increase the risk of severe infection. Therefore, it is under-
standable that in the early stages of the pandemic, patients on
conventional targeted systemic therapies were considered to
be at higher risk of severe COVID-19 infection. In addition to
risk-mitigating behaviours such as social distancing recom-
mended by the World Health Organization, those who were
thought to be more vulnerable, for instance those on
immunosuppressants, were advised to adopt stricter measures
of social isolation including distancing themselves from other
members of their household.2,3 There was a pressing need to
establish whether patients on immunosuppressive or
immunomodulatory medications should continue on their
medications.
By early 2020, international registries for patients with
IMIDs, such as PsoProtect and SECURE-AD Registry, had been
established for healthcare professionals to record cases of
COVID-19 and the impact of systemic treatments on outcomes
of the infection. Registry data have shown that patients on tar-
geted systemic treatment such as biologics do not appear to
be at increased risk of severe COVID-19 compared with those
on standard systemic agents or no treatment.4 Counterintu-
itively, patients receiving treatments that block cytokines such
as tumour necrosis factor and interleukin-17A appear to have
a lower rate of hospitalization from COVID-19.5 This could be
due to immunomodulatory effects of these drugs on the over-
production of cytokines that contribute to deleterious conse-
quences of severe COVID-19 infection. An alternative
explanation is behavioural – perhaps patients on biologics are
less likely to be exposed to the virus because of particularly
effective shielding.
PsoProtectMe and the CORE-UK study (COVID-19
Rheumatology Register) are online self-reporting registries
for patients with psoriasis and rheumatoid arthritis, respec-
tively, to record their experiences and behaviour during this
pandemic. In this issue of the BJD, Mahil et al. characterize
the shielding behaviours in 3720 participants with IMIDs
from 74 countries, and report on how these differ by treat-
ment type.6 Patients were divided into three treatment
groups: standard systemic agents (e.g. methotrexate), targeted
systemic treatments (biologics and Janus kinase inhibitors)
and no systemic treatment. Of the 3720 participants, 2262
reported shielding behaviour. Of those shielding, 1632 were
based in the UK and, interestingly, only 899 of them
reported having been specifically advised to shield. Along
with male sex, obesity and comorbidity burden, the investi-
gators found that the use of targeted systemic treatment was
most strongly associated with increased shielding behaviour,
compared with standard systemic therapy or no therapy. The
reasons for this are unclear, and further studies would be
useful to ascertain if there are differences in patient percep-
tion of risk across different treatment groups and why this
might be. Shielding correlated positively with anxiety and
depression, and inversely with larger households and cigar-
ette smoking, suggesting individual factors contribute, as well
as the advice received.
Despite the limitations of online self-reporting, for instance
access to and literacy in information technology, as well as
recall bias, this study provides valuable information both for
clinicians caring for patients with IMIDs during this pandemic,
and for public health agencies responsible for advising patients
on risk-mitigating behaviour. Registries such as PsoprotectMe
are vital in helping clinicians understand more about the com-
plicated relationships between psoriasis, its treatments, patient
behaviours and COVID-19 infection.
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